Canoe Software Inc. develops an artificial intelligence-based software solution for financial document and data management, primarily targeting allocators and investors in alternative assets. Founded in 2013 and based in New York, the company specializes in automating the collection, organization, and categorization of investment documents. Its software enables users to extract unstructured data from these documents and integrate it into various accounting and reporting platforms, enhancing data accuracy and operational efficiency. Canoe’s services cater to a diverse clientele, including single and multi-family offices, endowments, foundations, pensions, investment consultants, wealth managers, and financial institutions. By transforming PDF reports into actionable data, Canoe aims to improve the post-investment operational, monitoring, and reporting experience for its clients.
Vendr, Inc. is a Boston-based company that provides a software-as-a-service solution designed to manage the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr specializes in commercial negotiations, renewal management, and contract logistics, enabling companies to streamline their software acquisition efforts. By assisting organizations in purchasing and renewing software, Vendr helps them save both time and money, making it an essential partner for scaling companies. Its services are utilized by a range of fast-growing business-to-business and business-to-consumer companies, highlighting its effectiveness in the software procurement landscape.
Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.
Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.
Logixboard, Inc. is a Seattle-based company founded in 2016 that offers a cloud platform designed to enhance transparency and communication for freight forwarders. The platform addresses inefficiencies in the $2 trillion freight forwarding industry, where many firms rely on outdated methods such as paper, spreadsheets, and email for tracking shipments. By integrating with existing back-office applications, Logixboard's solution serves as a digital customer engagement layer, enabling freight forwarders to streamline their operations and improve customer service. The platform empowers companies to manage and control their freight operations more effectively, ultimately reducing costs and increasing efficiency in a traditionally low-tech industry.
Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.
Papaya is a developer of an online mobile bill payment application that simplifies financial transactions for users. The application supports various payment methods, including debit and credit cards and direct bank account transfers. It prioritizes security by encrypting personal information and payment data, ensuring compliance with HIPAA and PCI standards. In addition to its bill payment services, Papaya operates as an electronic money platform, offering digital solutions, online banking, and international payment services. This combination of features enables users to manage their financial activities efficiently and securely.
Lighthouse, operating under the name OTA Insight Ltd, specializes in providing cloud-based business intelligence solutions for the hospitality industry. Founded in 2012 and based in London, the company offers a suite of tools including Rate Insight, Parity Insight, and Revenue Insight, which help hoteliers make informed revenue and distribution decisions. These solutions utilize advanced data systems and forecasting algorithms to deliver real-time market demand forecasts, rate intelligence, and ranking analytics. With a strong emphasis on customer support, OTA Insight’s platform integrates seamlessly with various hotel management systems and data providers, supporting over 50,000 properties in 168 countries. Recognized as a leader in hospitality business intelligence, the company has garnered accolades and continues to empower hoteliers to optimize occupancy rates and enhance profitability.
AppliedVR, Inc. specializes in virtual reality solutions aimed at enhancing patient experiences in healthcare, specifically for managing pain and anxiety in various settings such as hospitals and surgery centers across the United States. Founded in 2013 and based in Los Angeles, the company has established partnerships with leading healthcare institutions, including Cedars-Sinai and Children's Hospital Los Angeles. Its therapeutic virtual reality platform has been utilized by over 20,000 patients in more than 250 hospitals and in eight countries. The technology is designed to address both acute and chronic pain, as well as anxiety related to medical procedures, offering clinically validated, on-demand solutions. Inspired by extensive academic research, AppliedVR seeks to redefine pain management practices in clinical environments and at home, aiming to establish itself as a leading digital health solution provider in this field.
Notable is an AI-powered healthcare startup focused on enhancing physician-patient interactions by automating and digitizing the recording of medical visits. The company's platform utilizes natural language processing and voice recognition technology to automatically capture and structure conversations between doctors and patients, facilitating the seamless update of electronic health records. Additionally, Notable's system recommends appropriate billing codes, streamlining administrative tasks for healthcare providers. By improving the efficiency of these interactions, Notable aims to allow physicians to dedicate more time to patient care rather than paperwork.
Centivo Corporation is a health plan administrator that provides innovative health insurance solutions for self-funded employers, employees, and clinicians. Founded in 2016 and based in Stamford, Connecticut, with additional offices in New York and Buffalo, the company aims to deliver high-quality, affordable healthcare by facilitating partnerships between employers and primary care teams. Centivo offers a comprehensive suite of services, including technology, claims processing, customer support, and population health management, to efficiently administer health benefits. Its model emphasizes collaboration between members and their primary care providers, encouraging cost-effective healthcare choices. Members benefit from personalized tools for patient-doctor matching and receive support through a user-friendly app and concierge services. Employers are supported by Centivo's commitment to eliminating waste and ensuring accountability in performance.
NOCD Inc. is a Chicago-based company that operates a mobile application designed to connect individuals with obsessive-compulsive disorder (OCD) to licensed mental health practitioners. Founded in 2014, the platform leverages cognitive behavioral therapy techniques, specifically exposure and response prevention exercises, to help users manage their symptoms. The application facilitates face-to-face video therapy sessions with therapists who specialize in OCD, while also providing 24/7 support through self-help tools and peer communities. NOCD aims to enhance the treatment experience for OCD patients by offering clinically supported resources and a comprehensive online platform dedicated to treatment and self-monitoring.
Developer of intelligent medical devices designed for treatment of Parkinson and motor dysfunction. With research and development of intelligent monitoring and assistant devices, the company develops systematic systematic solutions to functional disorders for patients with Parkinson and motor dysfunction, enabling patients to monitor their physical activities and facilitate their movements.
Innovusion, Inc. is a prominent developer of image grade LiDAR sensor systems, specifically designed for level 4 and 5 autonomous vehicles and advanced driver-assistance systems (ADAS). Founded in 2016 and based in Sunnyvale, California, Innovusion focuses on providing solutions that combine range, resolution, and hardware-accelerated sensor fusion within a compact and cost-effective framework. This unique approach makes their products suitable for the most demanding applications in the autonomous driving sector. As a venture-backed company, Innovusion is positioned at the forefront of innovation in the rapidly evolving automotive technology landscape.
Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.
Castor is an international health-tech company that offers a cloud-based clinical data platform designed to streamline the clinical trial process for researchers around the world. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries and has facilitated more than 4,000 studies across diverse therapeutic areas such as diabetes, cardiovascular diseases, rare diseases, infectious diseases, and oncology. Researchers using Castor generate substantial amounts of data from both traditional and remote trials, having reached significant milestones of 180 million data points and 2 million enrolled patients. The company's mission is to enhance the reusability of research data, supporting AI-driven clinical trials and ultimately maximizing the impact of data to improve medical research globally.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.
Proximie Inc., based in Bedford, Massachusetts, offers a secure software platform that facilitates virtual surgical collaboration among surgeons. By leveraging advanced telecommunication, augmented reality, artificial intelligence, and machine learning technologies, Proximie's platform enables real-time, peer-to-peer assistance during surgeries, regardless of location. This innovative approach allows surgeons to share expertise before, during, and after procedures, effectively overcoming the barriers of time and distance. Furthermore, the platform is compatible with various devices and software used in operating rooms, allowing for seamless integration and interaction. Proximie's mission is to enhance surgical knowledge and skills, enabling surgeons to refine their techniques in diverse settings, even with limited bandwidth.
1upHealth, Inc. is a health-tech company based in Boston, Massachusetts, founded in 2017. It operates a health data aggregation and centralization platform that facilitates the secure transmission of medical data between health systems and consumer applications. The platform consolidates health information from various electronic medical record systems, allowing users to control and share their digital health records with healthcare providers. Additionally, it enables providers to access and query the most current patient data from multiple connected health systems. The platform also supports software developers by providing access to clinical data from various clinics and hospitals, ultimately aiming to improve healthcare outcomes and reduce costs through better data utilization.
Zenflow, Inc. is a medical device company based in San Francisco, California, founded in 2014 by a team of Stanford University Biodesign Fellows in collaboration with leading urologists. The company focuses on developing and marketing a spring device designed to provide relief for permanent benign prostatic hyperplasia (BPH) symptoms in men. Zenflow's product addresses urinary obstruction without damaging surrounding tissues, offering a novel solution for patients and healthcare providers. The founders were motivated by the frustrations experienced by patients with existing treatment options, aiming to fulfill a significant unmet clinical need in urology.
Firefly Health, Inc. is a healthcare company based in Wellesley, Massachusetts, that specializes in primary health care services through an artificial intelligence-based platform. Founded in 2016, the company aims to redefine patient care by providing a virtual-first approach that combines advanced technology with a dedicated care team. Firefly Health offers services for common health conditions such as back pain, stomach flu, and women's health issues, facilitating live video appointments with primary care physicians without any membership fees. This model allows patients to navigate their health more effectively and make informed decisions, while enabling healthcare professionals to deliver consistent and proactive care.
OZiva is a plant-based Clean Nutrition Brand. The brand’s core differentiator lies in building a nutrition & fitness ecosystem that combines the best of ancient sciences such as Ayurveda, modern micronutrients, and an instantaneous digital community altogether.
Innovusion, Inc. is a prominent developer of image grade LiDAR sensor systems, specifically designed for level 4 and 5 autonomous vehicles and advanced driver-assistance systems (ADAS). Founded in 2016 and based in Sunnyvale, California, Innovusion focuses on providing solutions that combine range, resolution, and hardware-accelerated sensor fusion within a compact and cost-effective framework. This unique approach makes their products suitable for the most demanding applications in the autonomous driving sector. As a venture-backed company, Innovusion is positioned at the forefront of innovation in the rapidly evolving automotive technology landscape.
Yisheng Biopharma Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and marketing of immuno-oncology products and vaccines. Founded in 2002 and headquartered in Beijing, the company operates in China, the United States, Cambodia, and Singapore. Yisheng Biopharma utilizes its novel PIKA immunomodulating technology to enhance immune responses against cancers and infectious diseases. Key products under development include YS-ON-001, an investigational therapy aimed at treating advanced solid tumors, as well as YS-HBV-001, a vaccine for hepatitis B, and a PIKA-based rabies vaccine designed for rapid protection against rabies infection. The company's innovative approach targets multiple immune pathways to improve treatment outcomes.
Cohort, Inc. specializes in developing software that enhances chronic care management and clinical trials. The company's clinical AI and natural language processing technology analyzes electronic health records (EHR), extracting insights from diagnostics, medications, and clinical notes to provide tailored context for patients and their conditions. Cohort's platform streamlines the identification and enrollment of eligible patients, generates care plans automatically, and facilitates compliance and billing processes. By offering these solutions, Cohort enables primary care providers to improve the scale and efficiency of their chronic care management programs while also enhancing the identification and enrollment process for clinical trials. The company is headquartered in New York, with an additional office in San Francisco.
Metcela Inc. specializes in developing fibroblast-based therapies for cardiac diseases, focusing on regenerative medicine for conditions such as Ischemic Heart Disease. Founded in 2016 and based in Kawasaki-shi, Japan, the company utilizes VCAM-1-positive cardiac fibroblasts derived from patients' own cells. This innovative approach aims to replenish and restore damaged cardiac muscle and its surrounding microenvironment, enhancing the heart's natural healing capabilities. By repairing rather than replacing damaged cells, Metcela seeks to provide effective and cost-efficient treatments for heart failure, offering new hope for patients suffering from cardiac ailments.
Centivo Corporation is a health plan administrator that provides innovative health insurance solutions for self-funded employers, employees, and clinicians. Founded in 2016 and based in Stamford, Connecticut, with additional offices in New York and Buffalo, the company aims to deliver high-quality, affordable healthcare by facilitating partnerships between employers and primary care teams. Centivo offers a comprehensive suite of services, including technology, claims processing, customer support, and population health management, to efficiently administer health benefits. Its model emphasizes collaboration between members and their primary care providers, encouraging cost-effective healthcare choices. Members benefit from personalized tools for patient-doctor matching and receive support through a user-friendly app and concierge services. Employers are supported by Centivo's commitment to eliminating waste and ensuring accountability in performance.
Odaseva is a unified cloud data protection, compliance, and operations platform for enterprises running Salesforce. The company delivers enterprise-class data governance, providing data protection (backup and recovery, archiving, governor limits monitoring), data compliance for regulation requirements such as GDPR and data operations (Salesforce DX data extensions).
Odaseva was developed for Salesforce by Salesforce experts and is endorsed by Salesforce Ventures.
Carrot Fertility, Inc. provides comprehensive fertility benefits services to employers, supporting employees throughout their fertility healthcare journey globally. Founded in 2015 and headquartered in San Francisco, the company offers a range of services, including egg freezing, in vitro fertilization, adoption, donor, and gestational carrier services. Additionally, it features Carrot Rx, which facilitates a premium pharmacy experience for fertility medications, and Carrot Pregnancy, providing virtual access to experts and on-demand content. Carrot Card is a flexible benefits debit card that allows employees to pay for their care. By partnering with modern companies, Carrot Fertility enables organizations to customize fertility benefits that deliver financial, medical, and emotional support to employees seeking to become parents. The company also has offices in major cities around the world, including Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.
NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.
Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.
Rallybio, LLC is a biopharmaceutical company based in New Haven, Connecticut, that focuses on developing innovative therapies for patients with severe and rare disorders. Founded in 2018, the company is dedicated to addressing life-threatening conditions, particularly through its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT). This rare disease can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's research emphasizes the development of antibody, small molecule, and engineered protein therapies, primarily in the late discovery to early clinical stages. Through its efforts, Rallybio seeks to transform the lives of patients suffering from devastating diseases.
SonderMind LLC, founded in 2017 and based in Denver, Colorado, operates a digital platform that connects individuals with mental health professionals for both telehealth and in-person sessions. The company offers a comprehensive directory of therapists who provide services for a range of mental health issues, including anxiety, depression, PTSD, and more. SonderMind's platform aims to make behavioral health services more accessible and user-friendly, allowing consumers to easily find and schedule appointments with well-matched therapists. By streamlining the connection between clients and providers, SonderMind enhances the therapeutic experience while allowing therapists to concentrate on patient care without being burdened by administrative tasks.
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.
BenchSci Analytics Inc., founded in 2015 and based in Toronto, Canada, offers a research intelligence platform that leverages artificial intelligence and machine learning to assist scientists in navigating scientific literature for antibody usage data. By translating both closed and open-access data, the platform provides tailored recommendations for experiments, ultimately aiming to enhance the efficiency and success of biomedical research. BenchSci's technology is utilized by leading pharmaceutical companies and research institutions worldwide, significantly contributing to the acceleration of scientific discoveries. The company aspires to reduce the time it takes to bring medicines to patients by 50% by 2025, reflecting its commitment to advancing healthcare through innovative research solutions. BenchSci has garnered recognition as a top growth company and a favorable workplace, reflecting its impact and culture in the biotech industry.
Funnel Operation AB, founded in 2014 and headquartered in Stockholm, Sweden, specializes in marketing analytics and reporting software designed to automate data collection for marketers. The company's platform integrates with over 400 marketing and advertising sources, allowing users to streamline data feeding into various tools such as Business Intelligence systems, Data Warehouses, Google Sheets, Google Data Studio, and Google Analytics. Funnel's offerings include dashboards and reports for simplified marketing analysis, a data studio connector for aggregating marketing data, and APIs that facilitate data collection and distribution. The company serves a diverse clientele, including e-commerce businesses, media agencies, brands, B2B companies, mobile applications, and gaming firms, helping them manage advertising performance data effectively and gain insights for informed decision-making.
Oviva is a digital health company providing medically-oriented nutritional counseling services in Switzerland, Germany, and the United Kingdom. Founded in 2013 and headquartered in Ingenbohl, Switzerland, Oviva offers personalized behavior change programs aimed at managing diet and lifestyle-related health issues like obesity and diabetes. Their services are delivered through a network of qualified dietitians who work with clients both in clinics and remotely. The company has developed a smartphone application that allows users to engage with their dietitian, maintain a food diary, set health goals, and access tailored educational materials. This technology-enabled approach helps patients achieve better health outcomes while reducing the need for in-person appointments, ultimately lowering healthcare costs by preventing complications associated with these conditions.
Snapdocs, Inc. is a real estate technology company that provides a digital platform designed to streamline the mortgage closing process. Founded in 2012 and based in San Francisco, California, Snapdocs connects lenders, title and escrow companies, notary publics, and home buyers to enhance collaboration and efficiency in real estate transactions. The platform features advanced automation and standardized workflows, allowing participants to choose their preferred closing methods while improving accuracy and consumer satisfaction. It also enables notary signing agents to showcase their qualifications, helping them attract potential clients. By simplifying mortgage loan closings and improving the overall borrower experience, Snapdocs empowers its users to operate more effectively and transparently in a competitive market.
CareStack is a cloud-based platform designed to meet the comprehensive administrative and clinical needs of dental practices. It integrates various functionalities, including practice management, patient engagement, scheduling, telehealth conferencing, charting, automated reminders, claims processing, and business analytics, all within a single interface. This all-in-one solution is particularly beneficial for large and growing dental practices, helping them enhance productivity, reduce operational costs, and improve patient care. By centralizing and automating key processes, CareStack aims to elevate the financial success of dental offices while ensuring a streamlined experience for both patients and staff.
InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.
InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.
Buoy Health, Inc. is a health technology company based in Boston, Massachusetts, with an additional office in New York. Founded in 2014, Buoy Health specializes in artificial intelligence-driven digital health solutions that assist individuals in managing their health and healthcare options. The company offers a personalized online healthcare chatbot, known as Buoy Assistant, which analyzes symptoms, facilitates initial triage, and provides treatment recommendations. This platform enables users to conduct real-time assessments of their symptoms while simplifying the navigation of the healthcare system. Additionally, Buoy Health provides resources for employees through its Buoy Dashboard, allowing them to research benefits, access wellness programs, and connect with in-network providers. The service is available 24/7, making self-diagnosis and healthcare navigation straightforward and accessible.
Optimus Ride is a self-driving vehicle company based in Boston, Massachusetts, that focuses on developing technologies for efficient, sustainable, and equitable mobility systems. As a spinoff from the Massachusetts Institute of Technology, the company leverages over 30 years of interdisciplinary research in self-driving technologies, electric vehicles, and mobility-on-demand systems. Its technology integrates advancements in sensor fusion, mapping, computer vision, and machine learning, tailored for geofenced environments. The team comprises individuals with extensive industrial and entrepreneurial experience in areas such as manufacturing robotics, urban design, and shared vehicle fleet management, enabling diverse applications ranging from commercial vessel operations to transit solutions.
The leading provider of cyber risk management software, RiskLens empowers business executives, risk officers and CISOs to manage their organization's cyber risk from the business perspective by quantifying it in financial terms. RiskLens was founded in 2011 and is headquartered in Spokane, Washington.
ABK Biomedical Inc., founded in 2012 and based in Halifax, Canada, develops innovative embolotherapeutic products aimed at treating uterine fibroids, hypervascular tumors, and arteriovenous malformations. The company focuses on enhancing interventional radiology procedures, particularly embolization, by combining clinical market insights with advanced biomaterials. ABK Biomedical's flagship product is a novel radiopaque microsphere designed to improve the targeting of tumor blood vessels and tissue. This technology not only aids in the standardization and optimization of minimally invasive therapies but also facilitates personalized treatment options for patients with complex conditions. Through its commitment to advancing embolotherapy, ABK Biomedical seeks to transform patient care in the field of interventional radiology.
Vestwell is a digital retirement platform founded in 2016 and headquartered in New York, New York. It simplifies the offering and administration of 401(k) plans for advisors, employers, and employees by eliminating traditional challenges associated with retirement plan management. The platform features seamless plan design, automated onboarding, and streamlined administration, all while providing flexible investment strategies at competitive prices. By serving as a single point of contact, Vestwell enhances the retirement planning experience, ensuring that both plan sponsors and participants have their interests prioritized. Additionally, the platform supports registered investment advisors with automated compliance options tailored to the specific rules and regulations governing defined contributions.
Whatfix is a digital adoption platform that assists enterprises in enhancing their training and support initiatives by delivering contextual information in a user-friendly manner. The platform employs real-time interactive guidance technology to provide personalized, in-app user assistance, transforming traditional training and support methods. By offering just-in-time guidance, Whatfix enables users to complete tasks more efficiently across various applications, including web, desktop, and mobile. This approach fosters a unified digital workflow and self-help experience, leading to increased user adoption and productivity. Clients benefit from improved process compliance, reduced time for completing critical operations, and access to data-driven insights that support informed decision-making.
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. This technology allows for targeted alterations of single bases in the genome without creating double-stranded breaks in DNA, representing a potential advancement in genetic therapies. The company's pipeline includes programs aimed at treating serious diseases such as sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, and pediatric acute myeloid leukemia, as well as conditions like alpha-1 antitrypsin deficiency and certain central nervous system disorders. Beam Therapeutics is committed to providing life-long cures through its various approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Founded in 2017, Beam continues to build collaborations to enhance its research and development efforts.
Singular Genomics is a biotechnology company based in La Jolla, California, founded in 2016. It specializes in developing advanced gene sequencing technologies utilizing fluorescing molecular tags and novel next-generation sequencing and multiomics approaches. The company aims to empower researchers and clinicians through its innovative products, which include the G4 Sequencing Platform for next-generation sequencing and the PX Integrated Solution for single-cell analysis, spatial analysis, and proteomics. Singular Genomics is strategically located within a prominent biotech hub, adjacent to esteemed institutions such as the Salk Institute and UC San Diego, fostering collaboration and innovation in the rapidly growing genomics field. Its product offerings cater to a wide range of applications, including basic biology, oncology, and immunology, positioning the company as a key player in the life sciences sector.
Genomics PLC is focused on advancing the use of genomic data to transform healthcare. The company develops algorithms and software solutions that facilitate the analysis of large genomic and phenotypic datasets, aimed at understanding human biology and improving disease diagnosis and treatment. Its offerings serve a diverse range of clients, including governments, healthcare providers, pharmaceutical companies, and research laboratories. By providing tools that enhance the accuracy of genetic analysis, Genomics PLC helps de-risk the drug development process and enables clinicians to better identify individuals at risk for specific diseases. Founded in 2014 and based in Oxford, United Kingdom, the company aims to set standards in genomic data application, ultimately benefiting organizations and patients alike through innovative healthcare solutions.
Avidity Biosciences is a biopharmaceutical company specializing in the development of oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. Avidity's lead product candidate, AOC 1001, targets myotonic dystrophy type 1, a rare genetic muscle disorder. The company's development pipeline also includes programs focused on treating various muscle diseases, such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Additionally, Avidity is exploring therapeutic applications for immune and other cell types, leveraging its proprietary AOC platform to reach previously undruggable tissues and effectively target the genetic underpinnings of these conditions. Founded in 2012, Avidity Biosciences is headquartered in La Jolla, California.
Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.
Axoni is a New York-based technology firm focused on capital markets, specializing in distributed ledger solutions. Founded in 2013 by experts in distributed ledger technology and cryptography, Axoni serves major financial institutions and capital markets service providers. The company's offerings include the deployment of distributed ledger technology, custom smart contract development, and advanced analytics tools. Their software integrates traditional financial technologies with blockchain capabilities, providing market information and in-depth trend analysis. This comprehensive approach enables investment funders, exchange operators, and professional traders to enhance their systems for managing legal records, lifecycle events, and cash flow calculations.
RiskRecon is the only continuous vendor monitoring solution that delivers risk-prioritized action plans custom-tuned to match your risk priorities, providing the world’s easiest path to understanding and acting on third-party cyber risk. Partner with RiskRecon to build your scalable, third-party risk management program to realize dramatically better risk outcomes. To learn more about RiskRecon’s approach, request a demo or visit the website at www.riskrecon.com.
Simon Data is the enterprise Customer Data Platform (CDP) that empowers brands to deliver data-driven, personalized customer experiences anywhere.The platform leverages enterprise-scale big data and machine learning to power customer communications in any channel. Simon’s unique approach allows brands to develop and deliver incredible personalization capabilities without needing to build and maintain massive bespoke data infrastructure. At Simon, our goal is to improve and optimize customer experiences by making the entire process, experimentation through analysis, a data-driven one.
WelbeHealth is a healthcare organization dedicated to enhancing the quality of life for frail seniors through the PACE (Program of All-Inclusive Care for the Elderly) model. Founded by experienced physician entrepreneurs, the company provides comprehensive medical and social care, ensuring that participants receive coordinated support that includes medical and dental care, therapy services, transportation, and meal provisions. By focusing on the diverse needs of the elderly population, WelbeHealth aims to help them live longer, healthier, and more independent lives. The leadership team comprises professionals from prominent payer and provider organizations, reflecting a commitment to innovative and compassionate care. Through its holistic approach, WelbeHealth strives to unlock the potential of vulnerable seniors in the community, fostering an environment of empathy and support.
Unison is a provider of home-ownership investments that enables individuals to finance their homes without the burden of interest or monthly payments. Founded in 2004 and headquartered in San Francisco, California, Unison offers long-term investments in residential properties through innovative programs. These programs allow homeowners to share in the appreciation or depreciation of their property's value when they sell, creating a unique financial solution for those looking to purchase homes. By combining fintech origination capabilities with investment management, Unison aims to make homeownership more accessible and sustainable for a broader range of applicants.
Benchling, Inc. is a developer of a cloud-based informatics platform tailored for life sciences research and development. The platform encompasses a range of integrated applications that enable scientists to design, share, and document experiments efficiently. Key offerings include an electronic lab notebook for experiment documentation, a biological registration system for managing inventory like plasmids and antibodies, and analytical tools for visualizing and collaborating on structured data. Benchling's software supports cutting-edge research techniques such as CRISPR and CAR-T immunotherapy, facilitating advancements in biotherapeutics, biofuels, and biomaterials. The company's solutions are utilized by researchers in biotech and pharmaceutical companies, as well as academic and government labs, streamlining workflows and enhancing collaboration across various research projects. Founded in 2012, Benchling is headquartered in San Francisco, California.
Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response.
Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.
Protenus, Inc. is a Baltimore-based company that specializes in a healthcare compliance analytics platform designed to protect patient privacy and secure health data. Utilizing artificial intelligence, the platform audits every access to patient records across leading health systems in the United States. It enables healthcare organizations to gain comprehensive insights into the usage of health data, proactively identifying risks such as inappropriate access to patient information and potential theft or misuse of controlled substances by staff. By alerting compliance teams to policy violations and other anomalous behaviors, Protenus empowers hospitals to make informed decisions to enhance data protection and safeguard their institutions. The company, which was established in 2014 and previously known as Protenus, LLC, focuses on reducing risk and optimizing operational efficiency for its partner hospitals.
Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. Operating in the United Kingdom, European Union, and the United States, Orchard employs an autologous ex vivo gene therapy approach to transform patients’ hematopoietic stem cells into gene-modified products for treatment through a single administration. Its portfolio includes Strimvelis, the first approved gene therapy for adenosine deaminase-severe combined immunodeficiency (ADA-SCID), along with several products in clinical development targeting metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has a robust preclinical pipeline addressing various mucopolysaccharidosis types. Orchard collaborates with leading institutions in gene therapy, enhancing its research capabilities and clinical programs. Founded in 2015, Orchard Therapeutics continues to demonstrate a commitment to transforming the lives of patients through its advanced therapies.
Provider of speech and language therapy services intended for stunted children with speech disorder. The company provides early screening, clinical diagnosis, and therapeutic interventions to children with autism or speech disorder, enabling children to speak and communicate better.
Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who traditionally rely on insulin injections. Founded based on groundbreaking research by Professor Douglas Melton, the company has licensed a method to generate functional, insulin-producing beta cells in the laboratory. Semma Therapeutics aims to combine these proprietary cells with advanced devices to create a comprehensive therapy that can replace the missing beta cells without the need for immunosuppression. By striving to bring this transformative treatment to clinical application, Semma Therapeutics seeks to significantly enhance the lives of diabetes patients. Headquartered in Cambridge, Massachusetts, the company is a subsidiary of Vertex Pharmaceuticals and collaborates strategically with Defymed.
Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The platform enables users to select and enroll in various affordable health coverage options, including dental, vision, and prescription insurance plans. Stride Health simplifies the process of finding suitable health insurance by providing personalized recommendations and tax deduction support, thereby helping customers maximize their take-home pay. The company, originally known as Covered, Inc., rebranded to Stride Health in March 2013 and has since been based in San Francisco, California. Through its services, Stride Health aims to make healthcare accessible and manageable for its users.
Artemis Health Inc. is a health data analytics company that specializes in providing self-insured employers with actionable insights into their employee benefit programs. Founded in 2013 and headquartered in Salt Lake City, Utah, the company offers a platform that helps employers identify issues within their benefits programs, pinpoint opportunities for improvement, and track the effectiveness of implemented solutions. By leveraging their own benefits data, employers can make informed decisions aimed at reducing healthcare expenditures while enhancing the quality of health and wellness coverage for their employees. Artemis Health's approach aims to address inefficiencies in the U.S. healthcare system, ultimately supporting organizations in optimizing their benefit offerings.
Amphora Medical, Inc. is a Minnesota-based company that develops medical devices focused on treating female overactive bladder (OAB) syndrome. Founded in 2011 and headquartered in Maple Grove, Minnesota, the company is working on a novel cystoscopic device designed to enhance bladder function and improve the quality of life for patients suffering from OAB. Utilizing minimally invasive procedures and advanced cystoscopic technology, Amphora Medical aims to provide effective solutions for individuals affected by this condition.
Wellframe Inc. is a digital health management company based in Boston, Massachusetts, that specializes in care management solutions and digital concierge services. Founded in 2011, Wellframe develops mobile patient engagement software that enhances care management by connecting patients with their care teams through a user-friendly mobile application. The platform utilizes real-time member-generated data and artificial intelligence to create personalized care protocols and facilitate two-way communication, allowing for timely interventions and better patient monitoring. Wellframe's offerings include health plan solutions, such as daily health reporting, care team dashboards, and omni-channel communication tools, as well as operational services like system integration and analytics. Additionally, the company provides strategic consulting and change management services to help healthcare organizations improve their care delivery and patient engagement processes.
Checkmate Pharmaceuticals is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that specializes in developing novel immunotherapies for cancer treatment. Founded in 2015, the company focuses on leveraging CpG oligonucleotides to enhance anti-tumor T-cell responses and overcome the mechanisms that allow tumors to evade immune detection. By combining its proprietary technology with checkpoint inhibition, Checkmate aims to improve the efficacy of existing immunotherapies and provide new treatment options for patients. The company has formed strategic alliances with major pharmaceutical firms, including Merck KGaA and Pfizer, to further its research and development efforts in the field of cancer immunotherapy.
Quovo Inc. is a financial data platform that specializes in providing connectivity and insights for consumer financial accounts from over 14,000 institutions. Founded in 2009 and based in New York, Quovo's technology enables businesses to retrieve, organize, and analyze data, thereby enhancing their customer relationships and improving service personalization. The platform offers automated portfolio data management, including features like data normalization, reconciliation, and client onboarding through Autoverified Micro-deposits. Quovo serves a diverse clientele, including small- and mid-sized investors, endowments, family offices, and financial advisors. Its solutions are utilized by notable fintech companies and retail banks, making it a vital player in the digital finance landscape. In January 2019, Quovo became a subsidiary of Plaid Inc.
Medwell Ventures Private Limited is a provider of specialty home healthcare services in India, focusing on a range of therapeutic areas. Established in 2014 and headquartered in Bengaluru, the company offers a variety of wellness and care programs, including preventive screening, palliative care, and bedside nursing. Its services encompass 24×7 medical support, physician consultations, nursing care, laboratory sample collection and reporting, physiotherapy, medical devices, ambulance services, and pharmacy support. By integrating different healthcare delivery channels, Medwell Ventures aims to enhance the accessibility and personalization of medical treatment for patients with chronic diseases and diverse health profiles.
Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.
Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.
Cytek Biosciences, Inc. specializes in manufacturing and selling innovative flow cytometry tools and equipment for cancer and cell biology research. The company offers advanced instruments such as the Cytek Aurora and Cytek Northern Lights, which are full-spectrum flow cytometers designed for high-resolution and high-sensitivity cell analysis. Additionally, Cytek provides the DxP Athena system, which utilizes its proprietary technology to resolve dim populations in multicolor formats, along with the QbSure quality control program to ensure optimal performance of cytometers. The company also develops proprietary cFluor reagents that enhance the performance of its instruments in complex multicolor environments. Headquartered in Fremont, California, Cytek has expanded its global presence with locations in Maryland, the Netherlands, Japan, and China, aiming to make flow cytometry more accessible for researchers and clinicians worldwide.
Core Diagnostics Private Limited is a clinical laboratory based in Gurugram, India, established in 2012. The company specializes in next-generation diagnostics aimed at disease stratification and therapy selection. By employing advanced testing techniques, Core Diagnostics seeks to provide comprehensive diagnostic solutions and become a leading provider of high-end diagnostic services in the region.
Turnstone Biologics Inc. is a biotechnology company dedicated to developing viral immunotherapies aimed at enhancing cancer survival rates. Founded in 2015 and headquartered in Ottawa, Canada, with an additional office in New York, the company’s lead candidate, RIVAL-01, is based on a vaccinia virus backbone that incorporates three effective immunomodulators: Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine. These components are designed to synergistically stimulate immune responses and modify the tumor microenvironment to facilitate tumor eradication. Turnstone's platform leverages discoveries from prominent researchers in the field of oncolytic viral immunotherapy and has progressed RIVAL-01 into a Phase I/II clinical development study in collaboration with four Canadian academic institutions and the Fight Against Cancer Innovation Trust (FACIT).
Denali Therapeutics is a biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151, which are in various phases of clinical trials for Parkinson's disease. Additionally, Denali is developing DNL747, a selective RIPK1 inhibitor currently in Phase 1b trials for Alzheimer's and ALS. It also has programs focused on enzyme replacement therapy for MPS II and antibody transport vehicles targeting key proteins involved in neurodegeneration. Denali collaborates with various organizations, including Takeda Pharmaceutical Company and Genentech, to enhance its research efforts. Founded in 2013, Denali Therapeutics emphasizes a science-driven approach to address the complex challenges posed by neurodegenerative diseases, leveraging recent scientific insights and translational medicine tools.
US HealthVest is an innovative behavioral healthcare firm that has redefined the psychiatric hospital space. De novo strategies and acquisitions of operating facilities with unrealized potential are the core of the US HealthVest business model. Each facility is structured to offer multiple service lines in order to serve the needs of specific patient population groups. The senior management team of US HealthVest has successfully built psychiatric hospital businesses which were acquired by public companies. Ascend Health was founded by Richard Kresch, M.D. in 2005 and was one of the largest private psychiatric hospital providers with nine freestanding facilities and nearly 900 beds. Ascend Health was sold to Universal Health Services (NYSE: UHS) in 2012. The predecessor company, Heartland Health Developments, also focused on psychiatric care and was sold to Psychiatric Solutions in 2004.
Caribou Biosciences, Inc. is a biotechnology company based in Berkeley, California, specializing in cellular engineering and genome analysis through CRISPR-Cas9 technology. Founded in 2011, the company provides a gene editing platform that allows for targeted modifications in the genome. Its applications span various sectors, including human and animal therapeutics, agricultural biotechnology, and industrial biotechnology. Caribou's solutions facilitate the development of new disease models, enhance traits in plants, and support functional genomic screens. The company aims to advance both basic and applied biological research, leveraging its transformative capabilities to impact therapeutic development and bioproduction.
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.
Adagene (Suzhou) Limited is a clinical-stage biotechnology company based in Suzhou, China, focused on antibody discovery and engineering. The company specializes in developing immuno-oncology antibodies that target novel epitopes, utilizing its proprietary Smart Antibody Technology. This technology enhances the success rates of antibody development, significantly shortens the time required to bring products to market, and lowers associated costs. Adagene's offerings extend beyond therapeutic applications, as its technology is also applicable in diagnostics and research, aiming to advance the field of immunotherapy and improve patient outcomes. Founded in 2011, Adagene continues to innovate in the biopharmaceutical sector.
Toast, Inc. is a Boston-based company that specializes in developing a comprehensive point-of-sale and restaurant management platform tailored for the foodservice and hospitality industries. Founded in 2011, Toast provides cloud-based solutions that include online ordering, delivery tracking, tableside ordering, and labor management, all designed to streamline restaurant operations. The platform serves a diverse range of establishments, including restaurants, cafés, bars, and nightclubs, enabling them to enhance customer experiences and optimize business performance. By offering software subscription services, processing transaction fees, and providing financing through its Toast Capital division, Toast supports over 120,000 restaurant locations across the United States. The company stands out by processing a significant volume of financial transactions on its platform, reinforcing its commitment to delivering a robust and effective technology solution for restaurateurs.
VYNE Therapeutics is a late-stage biopharmaceutical company that specializes in the development and commercialization of serlopitant, a treatment for pruritus associated with various dermatologic conditions, including atopic dermatitis, psoriasis, and prurigo nodularis. The company aims to address a significant unmet medical need, as there are currently no approved therapies in the United States that specifically target pruritus in these conditions. In addition to its focus on dermatologic applications, VYNE is also investigating serlopitant for refractory chronic cough, a persistent cough that lasts more than eight weeks despite treatment. Serlopitant acts as a selective small molecule inhibitor of the neurokinin 1 receptor and is administered as an oral tablet once daily. The company has completed Phase II clinical trials for pruritus related to various conditions and is planning to advance into Phase III trials for prurigo nodularis, anticipating further data to support its clinical development. VYNE Therapeutics is headquartered in Redwood City, California, and was established in 2011.
Proteostasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cystic fibrosis and other diseases linked to protein homeostasis. The company’s primary product candidates include PTI-801, a CFTR corrector; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. Proteostasis employs theratyping to tailor treatment strategies based on individual responses to CFTR modulators, regardless of specific mutations. The company collaborates with the Cystic Fibrosis Foundation and Genentech to advance its research and development efforts. Founded in 2006 and based in Boston, Massachusetts, Proteostasis was previously known as Proteoguard, Inc. and rebranded in 2007. In December 2020, it was acquired by Yumanity Therapeutics in a reverse merger transaction.
Unum Therapeutics is a biopharmaceutical company focused on developing immunotherapy products for cancer treatment, utilizing proprietary T-cell engineering technology. The company’s lead programs, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, are in Phase I clinical trials. These include ACTR707 and ACTR087, both being tested in combination with rituximab for relapsed or refractory CD20+ non-Hodgkin lymphoma, as well as ACTR087 combined with SEA-BCMA for relapsed multiple myeloma. Additionally, ACTR707 is being evaluated with trastuzumab for HER2+ solid tumors. Unum Therapeutics is also exploring BOXR1030, a pre-clinical candidate targeting glypican-3 to enhance T cell functionality in the solid tumor microenvironment. Founded in 2014 and headquartered in Cambridge, Massachusetts, Unum aims to activate the body’s immune system to effectively combat cancer through its innovative therapies.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancermore
Dimension Therapeutics, Inc. is a gene therapy company dedicated to developing innovative treatments for rare and metabolic diseases linked to liver function. Founded in 2013 and based in Cambridge, Massachusetts, the company has established a robust pipeline of gene therapy candidates. Its lead products include DTX101 for hemophilia B and DTX201 for hemophilia A, alongside other programs targeting conditions such as ornithine transcarbamylase deficiency, glycogen storage disease type Ia, phenylketonuria, Wilson disease, and citrullinemia type I. Dimension Therapeutics collaborates with REGENX Biosciences, leveraging its extensive patent portfolio related to NAV vector technology. This partnership enhances Dimension's ability to advance its gene therapy initiatives, particularly in the realm of adeno-associated virus therapeutics. In 2017, Dimension Therapeutics became a subsidiary of Ultragenyx Pharmaceutical Inc.
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications.
It was founded in 2005 and headquartered in Cambridge, Massachusetts.
TraceLink, Inc. specializes in providing track and trace network solutions that enhance the life sciences supply chain and combat counterfeit prescription drugs. The company offers a range of products, including pharmaceutical serialization, drug tracking, and compliance solutions through its TraceLink Life Sciences Cloud. Key offerings include the Smart Rx Manager, which helps healthcare providers comply with the European Union Falsified Medicines Directive, and Serialized Product Intelligence, a cloud application that utilizes serialization data to identify supply chain issues and optimize operations. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers, and has established strategic partnerships with notable firms such as Amazon and KPMG. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink also has offices in the United Kingdom, India, Singapore, and Brazil. The company's platform is recognized for its ability to deliver global connectivity and visibility across the pharmaceutical supply chain, ensuring compliance and improving operational efficiency.
Recurly, Inc. specializes in providing subscription management and billing solutions designed to optimize revenue growth for businesses across various industries, including digital media, streaming, publishing, SaaS, and consumer goods. Founded in 2009 and headquartered in San Francisco, California, with additional offices in Boulder and New Orleans, the company offers a comprehensive platform that automates recurring billing processes, enhances payment acceptance, and reduces subscriber churn through effective card recycling strategies. Recurly's services allow businesses to quickly implement subscription billing systems, manage customer-related billing issues effortlessly, and gain actionable insights into their operations. As a level 1 PCI compliant service provider, Recurly also helps clients minimize costs and obligations associated with payment security. By streamlining these functions, Recurly enables businesses to focus on growth and improve their overall subscriber economics.
Aclaris Therapeutics is a clinical-stage biopharmaceutical company based in the United States, specializing in the development of innovative dermatologic and immunologic therapies. Founded by the team behind Vicept Therapeutics, Aclaris is dedicated to addressing significant unmet medical needs in dermatology and immunology, particularly in areas lacking FDA-approved treatments. The company operates in two main segments: therapeutics and contract research. The therapeutics segment focuses on creating novel drug candidates for immuno-inflammatory diseases, while the contract research segment generates revenue by providing laboratory services. Aclaris's pipeline includes drug candidates such as Zunsemetinib, an oral MK2 inhibitor, aiming to fill critical treatment gaps in the healthcare landscape.
Xulu, Inc. provides investment advisory services. The company offers personalized and data-driven recommendations to optimize clients’ 401(k) and IRA. It also provides financial projections; and personalized diversification plans for investments. The company was founded in 2010 and is based in Seattle, Washington. As of October 1, 2015, FutureAdvisor operates as a subsidiary of BlackRock, Inc.
Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing small molecule kinase inhibitors aimed at treating cancers and rare diseases driven by genomic abnormalities. The company’s pipeline includes avapritinib, which targets systemic mastocytosis and gastrointestinal stromal tumors, and BLU-263, an oral KIT inhibitor for indolent systemic mastocytosis and other mast cell disorders. Additionally, fisogatinib is in Phase I trials for advanced hepatocellular carcinoma, while pralsetinib targets RET-altered non-small cell lung cancer and medullary thyroid carcinoma. Other investigational compounds include BLU-782, aimed at treating fibrodysplasia ossificans progressive. Established in 2008 and based in Cambridge, Massachusetts, Blueprint Medicines utilizes its proprietary chemical library and Insights-to-Validation Platform to develop personalized therapies that address specific molecular drivers of cancer and the challenges posed by resistance mechanisms. The company has formed collaboration agreements with several pharmaceutical entities to enhance its research and development efforts.
Flywire operates an online payment platform that facilitates both domestic and international transactions, catering primarily to the education and healthcare sectors. The platform enables users, including international students and patients seeking medical care abroad, to make payments in various currencies through familiar online and offline options. By leveraging vertical-specific insights and technology, Flywire streamlines the payment process and enhances operational efficiency while minimizing risks associated with invoicing and payment reconciliation. The company, which was founded in 2009 and is headquartered in Boston, Massachusetts, has established partnerships with TRUE North and Adyen to bolster its offerings. With a significant portion of its revenue generated from the Americas, Flywire continues to expand its services to meet the needs of its diverse clientele.
Acacia Pharma is a hospital pharmaceutical company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of supportive care drugs for patients undergoing surgery, invasive procedures, or cancer treatments. The company’s lead product, BAREMSIS, is an intravenous formulation of amisulpride designed to prevent and treat post-operative nausea and vomiting. Other notable products include APD403, which has completed Phase II trials for chemotherapy-induced nausea and vomiting, and BYFAVO, an ultra-short-acting intravenous benzodiazepine anesthetic that has completed Phase III trials for use in procedures like colonoscopy and bronchoscopy. Acacia Pharma primarily serves anesthesiologists and oncologists, with a focus on addressing issues related to nausea, vomiting, cancer-related fatigue, and cachexia. Established in 2006, the company continues to innovate in the field of cancer supportive care.
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.
Kyruus, Inc. is a provider of web-based software solutions focused on optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010 and headquartered in Boston, Massachusetts, Kyruus offers a suite of analytically driven products designed to enhance the engagement, management, and performance of healthcare providers. Its solutions include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which provides administrators with tools to monitor and analyze physician performance. Additionally, the company offers Kyruus MDSeekyr for identifying high-value providers and Kyruus Insight Reports for evaluating physician network trends and performance. The ProviderMatch suite further aids hospitals in connecting patients with the most suitable providers, ensuring a seamless patient experience while aligning provider availability with patient demand. Through its proprietary data management platform, Kyruus leverages accurate data to facilitate effective appointments and enhance overall patient care.
Ultragenyx Pharmaceutical is a biopharmaceutical company based in the United States that focuses on developing therapeutics for rare and ultra-rare diseases, particularly serious genetic conditions. The company identifies, acquires, and commercializes novel treatments, leveraging existing scientific knowledge to address unmet medical needs in this challenging area. Its portfolio includes several medicines such as Crysvita, which treats X-linked hypophosphatemia in both adults and pediatric patients, Dojolvi, and Mepsevii, indicated for Mucopolysaccharidosis VII. Ultragenyx aims to create impactful therapeutics by employing effective development strategies tailored to the complexities of rare diseases.
Innovent Biologics, Inc. is a prominent biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacture, and commercialization of monoclonal antibody drug candidates. The company focuses on various therapeutic areas, including oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody used in treating multiple cancers and is featured on the National Reimbursement Drug List. Innovent has developed several other promising candidates, including biosimilars and bispecific antibodies for conditions such as non-Hodgkin’s lymphoma, autoimmune diseases, and advanced solid tumors. The company has established strategic collaborations with major global pharmaceutical firms, enhancing its research and development capabilities. Founded in 2011, Innovent has a strong management team with extensive experience in biologics, and it continues to expand its portfolio of therapeutic options while maintaining a commitment to innovation in the biopharmaceutical industry.